文献速递脑血管病

急性缺血性卒中发病超6小时血管内取栓的真实世界经验

Endovascular Thrombectomy for Acute Ischemic Stroke Beyond 6 Hours From Onset: A Real-World Experience.
PubMed 文献 · Stroke · 2020-06-17

该研究基于意大利血管内取栓登记数据,纳入327例发病超6小时且经CT灌注和侧支循环评估筛选的大血管闭塞患者,发现90天功能独立达41.3%,症状性颅内出血6.7%,3个月病死率17.1%,提示超6小时取栓可行且安全。

要点

  • 超6小时取栓患者90天功能独立(mRS 0-2)比例为41.3%。
  • 超6小时取栓症状性颅内出血发生率6.7%,3个月病死率17.1%。
  • 超6小时取栓患者功能独立概率显著低于6小时内取栓患者。

核心结论

  • 在经CT灌注和侧支循环评估筛选的大血管闭塞患者中,发病超6小时血管内治疗可行且安全,症状性颅内出血未增加。

研究设计与样本

  • 回顾性真实世界研究,从意大利血管内取栓登记中提取发病超6小时且改良Rankin量表评分≤2、ASPECTS≥6的患者数据。
  • 共纳入3057例患者,其中327例在发病超6小时后接受治疗。

主要发现

  • 超6小时治疗组平均年龄66.8±14.9岁,基线NIHSS中位数16,发病至腹股沟穿刺时间中位数430分钟。
  • 最常见闭塞部位为大脑中动脉(45.1%)。
  • 超6小时治疗组90天功能独立(mRS 0-2)比例为41.3%,症状性颅内出血发生率6.7%,3个月病死率17.1%。
  • 超6小时治疗组获得功能独立(mRS 0-2)的比值比为0.58(95%CI 0.43-0.77),显著低于6小时内治疗组。
  • 6-12小时组(278例)与12-24小时组(49例)的结局无差异。

关键数值与推荐

  • 功能独立定义为90天改良Rankin量表评分0-2。
  • 超6小时治疗组功能独立比值比为0.58(95%CI 0.43-0.77),显著低于6小时内治疗组。
  • 超6小时治疗组症状性颅内出血发生率为6.7%,3个月病死率为17.1%。
  • 超6小时与6小时内治疗组在再通率和安全结局方面无差异。

临床怎么用

  • 对于发病超6小时的前循环大血管闭塞患者,可结合CT灌注错配和侧支循环评估个体化筛选后行血管内取栓。
  • 超6小时取栓虽功能独立概率低于早期治疗,但症状性颅内出血和病死率在可接受范围。
  • 6-12小时与12-24小时时间窗患者的结局无显著差异,支持延长时间窗的个体化决策。

局限性

  • 本研究为真实世界回顾性登记研究,非随机对照设计。
  • 超6小时组样本量相对较小(327例),尤其12-24小时组仅49例。
  • 患者筛选基于CT灌注和侧支循环评估的个体化判断,存在选择偏倚可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: To evaluate outcome and safety of endovascular treatment beyond 6 hours of onset of ischemic stroke due to large vessel occlusion in the anterior circulation, in routine clinical practice. METHODS: From the Italian Registry of Endovascular Thrombectomy, we extracted clinical and outcome data of patients treated for stroke of known onset beyond 6 hours. Additional inclusion criteria were prestroke modified Rankin Scale score ≤2 and ASPECTS score ≥6. Patients were selected on individual basis by a combination of CT perfusion mismatch (difference between total hypoperfusion and infarct core sizes) and CT collateral score. The primary outcome measure was the score on modified Rankin Scale at 90 days. Safety outcomes were 90-day mortality and the occurrence of symptomatic intracranial hemorrhage. Data were compared with those from patients treated within 6 hours. RESULTS: Out of 3057 patients, 327 were treated beyond 6 hours. Their mean age was 66.8±14.9 years, the median baseline National Institutes of Health Stroke Scale 16, and the median onset to groin puncture time 430 minutes. The most frequent site of occlusion was middle cerebral artery (45.1%). Functional independence (90-day modified Rankin Scale score, 0-2) was achieved by 41.3% of cases. Symptomatic intracranial hemorrhage occurred in 6.7% of patients, and 3-month case fatality rate was 17.1%. The probability of surviving with modified Rankin Scale score, 0-2 (odds ratio, 0.58 [95% CI, 0.43-0.77]) was significantly lower in patients treated beyond 6 hours as compared with patients treated earlier No differences were found regarding recanalization rates and safety outcomes between patients treated within and beyond 6 hours. There were no differences in outcome between people treated 6-12 hours from onset (278 patients) and those treated 12 to 24 hours from onset (49 patients). CONCLUSIONS: This real-world study suggests that in patients with large vessel occlusion selected on the basis of CT perfusion and collateral circulation assessment, endovascular treatment beyond 6 hours is feasible and safe with no increase in symptomatic intracranial hemorrhage.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Casetta I, Fainardi E, Saia V, et al. Endovascular Thrombectomy for Acute Ischemic Stroke Beyond 6 Hours From Onset: A Real-World Experience. Stroke. 2020. PMID: 32568647. doi:10.1161/STROKEAHA.119.027974

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。